EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

3p25.3 microdeletion of GABA transporters SLC6A1 and SLC6A11 results in intellectual disability, epilepsy and stereotypic behavior



3p25.3 microdeletion of GABA transporters SLC6A1 and SLC6A11 results in intellectual disability, epilepsy and stereotypic behavior



American Journal of Medical Genetics. Part A 164a(12): 3061-3068



Small interstitial deletions affecting chromosome region 3p25.3 have been reported in only five patients so far, four of them with overlapping telomeric microdeletions 3p25.3 and variable features of 3p- syndrome, and one patient with a small proximal microdeletion and a distinct phenotype with intellectual disability (ID) and multiple congenital anomalies. Here we report on three novel patients with overlapping proximal microdeletions 3p25.3 of 1.1-1.5 Mb in size showing a consistent non-3p- phenotype with ID, epilepsy/EEG abnormalities, poor speech, ataxia and stereotypic hand movements. The smallest region of overlap contains two genes encoding sodium- and chloride-dependent GABA transporters which have not been associated with this disease phenotype in humans so far. The protein function, the phenotype in transporter deficient animal models and the effects of specific pharmacological transporter inhibition in mice and humans provide evidence that these GABA transporters are plausible candidates for seizures/EEG abnormalities, ataxia and ID in this novel group of patients. A fourth novel patient deleted for a 3.16 Mb region, both telomeric and centromeric to 3p25.3, confirms that the telomeric segment is critical for the 3p- syndrome phenotype. Finally, a region of 643 kb is suggested to harbor one or more genes causative for polydactyly which is part of the 3p- syndrome.

(PDF emailed within 0-6 h: $19.90)

Accession: 051044329

Download citation: RISBibTeXText

PMID: 25256099

DOI: 10.1002/ajmg.a.36761



Related references

De novo loss-of-function mutations in SETD5, encoding a methyltransferase in a 3p25 microdeletion syndrome critical region, cause intellectual disability. American Journal of Human Genetics 94(4): 618-624, 2014

Ade novo357 Mb microdeletion in 8q123q132 in a patient with mild intellectual disability and epilepsy. 2011

A de novo 3.57 Mb microdeletion in 8q12.3q13.2 in a patient with mild intellectual disability and epilepsy. European Journal of Medical Genetics 55(5): 358-361, 2012

RORB gene and 9q21.13 microdeletion: report on a patient with epilepsy and mild intellectual disability. European Journal of Medical Genetics 57(1): 44-46, 2014

15q26.1 microdeletion encompassing only CHD2 and RGMA in two adults with moderate intellectual disability, epilepsy and truncal obesity. European Journal of Medical Genetics 57(9): 520-523, 2015

Assessment of 2q23.1 microdeletion syndrome implicates MBD5 as a single causal locus of intellectual disability, epilepsy, and autism spectrum disorder. American Journal of Human Genetics 89(4): 551-563, 2011

Mutations in the GABA Transporter SLC6A1 Cause Epilepsy with Myoclonic-Atonic Seizures. American Journal of Human Genetics 96(5): 808-815, 2015

Association of Seizure Occurrence with Aneurysm Treatment Modality in Aneurysmal Subarachnoid Hemorrhage Patients. Neurocritical Care, 2018

Interstitial 3p25.3-p26.1 deletion in a patient with intellectual disability. American Journal of Medical Genetics. Part A 158a(10): 2587-2590, 2013

Epilepsy in children with intellectual disability in Bosnia and Herzegovina: effects of sex, level and etiology of intellectual disability. Research in Developmental Disabilities 30(5): 1078-1083, 2009

Deletion of 3p25.3 in a patient with intellectual disability and dysmorphic features with further definition of a critical region. American Journal of Medical Genetics. Part A 161a(6): 1405-1408, 2016

Central nervous system medication use in older adults with intellectual disability: Results from the successful ageing in intellectual disability study. Australian and New Zealand Journal of Psychiatry 50(4): 352-362, 2015

Clinical usefulness of the diagnostic manual-intellectual disability for mental disorders in persons with intellectual disability: results from a brief field survey. Journal of Clinical Psychiatry 70(7): 967-974, 2009

Frailty and disability in older adults with intellectual disabilities: results from the healthy ageing and intellectual disability study. Journal of the American Geriatrics Society 60(5): 934-938, 2012

Patterns of multimorbidity in an older population of persons with an intellectual disability: results from the intellectual disability supplement to the Irish longitudinal study on aging (IDS-TILDA). Research in Developmental Disabilities 34(1): 521-527, 2013